What Has Research Shown About BPC-157 and Angiogenesis?

What does angiogenesis mean in the BPC-157 literature?

Angiogenesis is the growth of new blood vessels from existing vasculature. In the BPC-157 corpus it is rarely studied as an outcome in its own right. It is studied as a proposed intermediate step: the argument running through three decades of animal work is that poorly vascularised soft tissue repairs poorly, so a compound that raises vessel density at an injury site would change how those tissues recover. A 2014 review from the originating Zagreb group described BPC-157 as an “angiomodulatory” agent acting through several vasoactive systems, including nitric oxide, VEGF and focal adhesion kinase, rather than as a single-pathway growth factor (source 5).

That framing matters when reading the evidence. Steadfast Research Group supplies BPC-157 as a research-grade material for laboratory work, and the angiogenesis strand is the one most often cited to explain results in other models, including tendon, muscle and gastrointestinal work, rather than a body of research carrying a clinical endpoint of its own.

Which assays have researchers used to measure BPC-157 and vessel growth?

Four experimental approaches account for most of the published vascular data:

Chick chorioallantoic membrane (CAM) assay

A long-established in-vivo vascular assay performed on the membrane of a fertilised chicken egg, in which vessel density is scored directly (source 1).

Endothelial tube-formation assay

Cultured vascular endothelial cells are plated on a basement-membrane matrix and the network of tube-like structures they form is quantified (sources 1, 2, 7).

Rat hind-limb ischaemia

Perfusion of a surgically ischaemic limb is followed by laser Doppler scanning, with vessel counts confirmed on histology (source 1).

Immunohistochemistry at an injury site

Vessel and endothelial markers such as CD34 and factor VIII, alongside VEGF, are stained in repairing muscle and tendon (source 3).

What did the chorioallantoic membrane and tube-formation assays report?

The most cited single paper is a 2017 study in the Journal of Molecular Medicine from a group at Chang Gung University in Taiwan (source 1). Using the CAM assay in vivo and an endothelial tube-formation assay in vitro, the researchers reported that BPC-157 raised vessel density in both. In human vascular endothelial cells they observed increased mRNA and protein expression of vascular endothelial growth factor receptor 2 (VEGFR2) but no increase in VEGF-A itself, which is to say the receptor moved and the ligand did not.

The same study reported that BPC-157 promoted internalisation of VEGFR2, and that both the internalisation and the rise in tube formation were blocked when dynasore, an inhibitor of endocytosis, was present. Time-dependent activation of the VEGFR2-Akt-eNOS signalling pathway was suppressed by dynasore as well. That internalisation step is the part of the account later work has built on.

What did the rat hind-limb ischaemia model report?

In the same 2017 paper, BPC-157 was given to rats with surgically induced hind-limb ischaemia. Laser Doppler scanning showed faster recovery of blood flow in the peptide group, and histological analysis of the limb muscle showed a greater number of vessels together with increased vascular expression of VEGFR2 (source 1). This is the most direct functional vascular measurement in the corpus, because perfusion is an outcome rather than a marker of one.

Why did one study report no direct angiogenic effect in cell culture?

A 2009 study in the Journal of Physiology and Pharmacology examined angiogenesis in crushed muscle and in transected muscle and tendon, alongside cell-culture work (source 3). The cell-culture result was negative: the authors reported no direct angiogenic effect of BPC-157 on cell cultures. In vivo, immunohistochemistry using VEGF, CD34 and factor VIII antibodies showed what the authors called adequately modulated angiogenesis in the animals given the peptide, and they concluded that the angiogenic potential was tied to the repair process in vivo, with BPC-157 acting by up-regulating VEGF expression.

That sits in direct tension with the 2017 and 2015 in-vitro results, both of which did report effects on cultured endothelial cells. The discrepancy has not been formally reconciled. Candidate explanations include different cell types, concentrations and assay formats, but no published head-to-head study has tested them. A researcher citing the claim that BPC-157 is pro-angiogenic in vitro is citing a claim at least one primary study contradicts.

How do the main angiogenesis studies compare?

What has research reported about VEGF expression in wound models?

A 2015 study in Drug Design, Development and Therapy applied BPC-157 topically in a rat alkali-burn skin model (source 2). At day 18 after wounding, histological examination with haematoxylin-eosin and Masson staining showed greater granulation tissue formation, re-epithelialisation, dermal remodelling and collagen deposition than in the model control group, and the authors reported raised VEGF expression in the wounded skin tissue. In parallel in-vitro work on human umbilical vein endothelial cells they reported increased proliferation and migration and accelerated vascular tube formation, and implicated ERK1/2 phosphorylation along with its downstream targets c-Fos, c-Jun and Egr-1.

Egr-1 also appears in the earliest paper in this group. A 2007 study in the European Journal of Pharmacology compared PL 14736, the pharmaceutical designation used for this peptide at the time, against recombinant human PDGF-BB in a rat sponge-granuloma model and in full-thickness excisional wounds in db/db genetically diabetic mice (source 4). The two were similarly selective for stimulating granulation tissue, while PL 14736 was more active on early collagen organisation, and it induced egr-1 and its repressor nab2 in Caco-2 cells more rapidly than PDGF-BB did. That work came out of Pliva, a pharmaceutical company, rather than an academic peptide laboratory.

What newer molecular mechanism has been proposed?

A 2026 paper in Cell Communication and Signaling proposed a route that does not run through VEGFR2 at all (source 7). The authors reported that intracellular BPC-157 engages FBXO22, an E3 ubiquitin ligase adaptor protein, through the proline residue at position 3 of the peptide, and that the resulting complex suppresses ubiquitination and proteasomal degradation of the transcription factor BACH1. Accumulated BACH1 was reported to raise proliferation and tube-forming capacity in vascular endothelial cells. The role of the position-3 proline was tested experimentally rather than inferred.

This is one paper, published recently, and it has not been independently replicated. It appears here because it is the first account in this corpus to name a specific intracellular binding partner, which makes it falsifiable in a way the earlier pathway descriptions are not.

Is BPC-157 described as pro-angiogenic or angiomodulatory?

Both descriptions appear in print, and the difference between them is contested. The pro-angiogenic reading rests on the vessel-density and perfusion results above. The angiomodulatory reading is argued mainly by the originating group, which holds that vessel growth is directed rather than simply increased. Their strongest stated example is the cornea. A 2025 paper set out a conceptual framework in which corneal transparency and the cornea’s “angiogenic privilege” are preserved during repair, and reported that BPC-157 did not produce corneal neovascularisation but opposed it (source 15). A companion 2025 review made a parallel argument about the nitric oxide system, describing an effect on NO levels that ran in either direction depending on context (source 8).

Read closely, that is a strong claim. A compound that raises vessel counts in ischaemic muscle while lowering them in cornea would be doing something more specific than stimulating endothelium, and the supporting publications come almost entirely from one group. No independent laboratory has tested it.

What published disagreement exists about angiogenesis and tumour risk?

The clearest disagreement in this literature was published as a formal exchange in Pharmaceuticals during 2025. A February 2025 literature and patent review by a Polish group summarised the reported activities of BPC-157 and raised questions about its probable toxicity (source 9). Sikiric and colleagues then published a comment in the same journal stating that they were defending the peptide against what they characterised as speculation running from angiogenesis toward tumorigenesis, and arguing the opposite case, that anti-tumour effects had been observed in vivo and in vitro (source 10). The original authors published a reply (source 11).

For a researcher the useful part is not which side prevailed. It is that both sides are reasoning from the same finding: new vessel growth is cited as the mechanism behind repair and as the mechanism behind the risk. Any experimental design in this area has to account for both readings rather than only the favourable one.

What are the limits of the angiogenesis evidence?

The most important limit is that no human study has measured an angiogenesis endpoint. A 2025 systematic review in HSS Journal screened 544 articles published between 1993 and 2024 and included 36 studies, of which 35 were preclinical and one clinical, grading the included work at level IV and level V (source 12). A 2025 narrative review independently counted three pilot studies in humans, covering intra-articular knee pain, interstitial cystitis, and intravenous safety and pharmacokinetics, none of which examined vessel growth (source 16). A 2026 biopharmaceutical review put total human exposure at fewer than 30 subjects across three uncontrolled pilot studies and recorded no completed Phase II trial (source 13).

Two further caveats bear specifically on vascular work. The same 2026 review described a pharmacokinetic-pharmacodynamic disconnect, a plasma half-life under 30 minutes set against biological effects reported to last hours to days, which remains unexplained and complicates the timing of any vascular experiment (source 13). A 2019 review in Cell and Tissue Research separately noted that only a handful of research groups had performed in-depth studies of the peptide across the preceding two decades (source 17).

On that second point the angiogenesis strand is unusually well placed compared with the rest of the BPC-157 corpus. Of the primary studies cited here, the 2017 and 2020 work from Taiwan, the 2015 and 2026 work from China, the 2007 Pliva study and the 2026 Turkish arterial study were all produced by groups with no author overlap with the originating Zagreb laboratory. What is missing is not independence but a human vascular endpoint. The 2020 Taiwanese study reported concentration-dependent, endothelium-dependent vasodilation in isolated rat aorta, abolished by L-NAME or haemoglobin and attributed to a Src-caveolin-1-eNOS pathway (source 6). The closest approach to human tissue so far reported the same endothelium- and NO-dependence in rings of internal mammary artery recovered from twelve coronary bypass operations, and that measured vasorelaxation rather than vessel growth (source 14).